Prevention of chronic rejection in mouse aortic allografts by combined treatment with CTLA4-Ig and anti-CD40 ligand monoclonal antibody

Transplantation. 1997 Dec 27;64(12):1838-43. doi: 10.1097/00007890-199712270-00035.

Abstract

Background: In this study, using a murine model of aortic allotransplantation, the role of blockade of signaling through CD28/B7 and CD40/CD40 ligand costimulatory pathways in the evolvement of posttransplant vasculopathy was examined.

Methods: Aortic allografts were transplanted across C57BL/1OJ (H2b)-->C3H (H2k) strain combinations. Transient or more stable blockade of second signaling was achieved by either a single injection or multiple injections of CTLA4-Ig fusion protein (200 microg/dose i.p.) and/or anti-CD40 ligand (CD40L) monoclonal antibody (250 microg i.m.). At day 30 after transplantation, the grafts were harvested for histopathological and immunohistochemical examination.

Results: Similar to allografts of untreated animals, aortic allografts obtained from recipients treated with either CTLA4-Ig or anti-CD40L monoclonal antibody alone exhibited marked narrowing of the lumen primarily due to concentric intimal thickening caused by proliferation of alpha-smooth muscle actin-positive cells. Contemporaneous treatment, however, with either a single injection or multiple injections of CTLA4-Ig and anti-CD40L monoclonal antibody resulted in marked diminution of intimal thickening. Interestingly, concurrent prolonged inhibition of CD28/B7 and CD40/CD40L pathways resulted in complete abrogation of the development of posttransplant arteriopathy.

Conclusion: These data suggest that a more stable disruption of signaling through costimulatory pathways may be required to obviate the development of posttransplant vasculopathy.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Abatacept
  • Animals
  • Antibodies, Monoclonal / therapeutic use*
  • Antigens, CD
  • Antigens, Differentiation / administration & dosage*
  • Aorta / transplantation*
  • CD40 Ligand
  • CTLA-4 Antigen
  • Chronic Disease
  • Drug Administration Schedule
  • Graft Rejection / prevention & control*
  • Immunoconjugates*
  • Immunosuppression Therapy / methods*
  • Male
  • Membrane Glycoproteins / immunology*
  • Mice
  • Mice, Inbred C3H
  • Mice, Inbred C57BL
  • Signal Transduction
  • Tumor Necrosis Factor Receptor Superfamily, Member 7 / physiology

Substances

  • Antibodies, Monoclonal
  • Antigens, CD
  • Antigens, Differentiation
  • CTLA-4 Antigen
  • Ctla4 protein, mouse
  • Immunoconjugates
  • Membrane Glycoproteins
  • Tumor Necrosis Factor Receptor Superfamily, Member 7
  • CD40 Ligand
  • Abatacept